GammaCan To Present at Rodman and Renshaw 2nd Annual Global Healthcare
Conference; CEO Dr. Dan J. Gelvan To Showcase Company to Over 800 Expected
Institutional Investors
GIVAT SHMUEL, Israel, Apr 20, 2005 (BUSINESS WIRE) -- GammaCan International,
Inc. (OTC BB: GCAN), a developer of immunotherapies for cancer and other serious
conditions, today announced that Dr. Dan J. Gelvan, CEO, will present at the
Rodman and Renshaw 2nd Annual Global Healthcare Conference on May 4th
and 5th in Paris, France.
The 2nd Annual Global Healthcare Conference follows on from the success of last
year's conference held in London. That event attracted more than 150 presenting
companies and was attended by more than 800 participants, including
institutional investors, venture capitalists and senior corporate executives as
well as experts from the scientific and medical communities.
"We are honored to have the opportunity to bring GammaCan's IVIg-based product
and investment provocation to the attention of a group of world-class
institutional investors and members of the scientific community. Rodman and
Renshaw provides us with a unique platform in which we can address global
leaders," stated Dan J. Gelvan, CEO.
About Rodman and Renshaw
Rodman and Renshaw, L.L.C. is a privately held, full-service investment bank
committed to fostering the long-term success of emerging growth companies
through capital raising, strategic advice, insightful research, and the
development of institutional support. Over the last two years, Rodman and
Renshaw completed over 60 financing transactions, totaling in excess of $1
billion. Rodman and Renshaw concentrates on emerging growth companies in the
life science and technology sectors.
About GammaCan
GammaCan is focusing on the commercialization of a revolutionary anti-cancer
immunotherapy that the Company believes will be proven to be effective in
reducing the metastastic spread of a wide range of cancers. GammaCan's proposed
treatment is based in IVIg, a safe, relatively non-toxic human plasma-based
product, currently used to treat a variety of immune deficiencies and autoimmune
diseases. It works by strengthening the patient's immune system. Many experts
currently view immunotherapy as a future alternative to today's standard
chemotherapy. Approximately twenty companies produce IVIg, and annual worldwide
sales are currently in excess of 50 metric tons with an estimated value in
excess of 1.5 billion USD. IVIg is commonly used to treat certain autoimmune
diseases and blood disorders and to replace the antibodies in people who are
unable to produce them. For more information about Gammacan visit
gammacan.com or call the company's headquarters in Givat Shmuel,
Israel at 972-3-5774475.
SOURCE: GammaCan International
CONTACT: Investor Contact:
DeMonte Associates
Cynthia DeMonte, 212-605-0525
cdemonte@aol.com
www.demonte.com
. |
